2024 Asia Conference on Lung Cancer (ACLC) - Poster & ePosters-PP01.60

PP01.60 - Huixia Li

Pdf Summary

This systematic review and meta-analysis, conducted by Huixia Li and colleagues, investigates the impact of DNA Damage Response and Repair (DDR) gene mutations on the efficacy of immunotherapy in non-small cell lung cancer (NSCLC). The study addresses the need for effective biomarkers to predict the response to immunotherapy, emphasizing that such predictors are currently scarce. It explores the role of DDR deficiencies in enhancing tumor recognition by the immune system through the generation of neoantigens and the upregulation of PD-L1 expression, which are critical to the body's immune response to tumors.<br /><br />The analysis reveals that NSCLC patients with DDR gene mutations generally show improved outcomes when treated with immunotherapy. This improvement suggests that DDR mutations could potentially serve as predictive biomarkers, helping clinicians to identify which patients might respond better to immunotherapy. The study focuses on clinical outcomes such as Objective Response Rate, Progression-Free Survival, and Overall Survival among patients with these mutations.<br /><br />However, the study acknowledges certain limitations, including reliance on published data rather than individual patient data, which affects its internal validity. Additionally, it incorporates studies involving combination therapies with chemotherapy and recognizes the challenge of distinguishing between different DDR mutations due to limited available studies. While these factors might introduce minor differences in efficacy, they highlight areas for further research to refine predictive capabilities.<br /><br />Overall, the findings suggest a promising avenue for using DDR gene mutations to tailor immunotherapy treatments in NSCLC, potentially improving the precision and effectiveness of cancer treatment strategies.

Keywords

DNA Damage Response

DDR gene mutations

immunotherapy

non-small cell lung cancer

NSCLC

biomarkers

tumor recognition

PD-L1 expression

clinical outcomes

precision medicine